2026-01-28 - Analysis Report
**Company Overview**
International Business Machines Corporation (IBM) is an American multinational technology company, one of the largest and most successful technology companies in the world.

**Return Rate Analysis**
Comparison of the return rate of IBM (ticker = IBM) with the return rate of S&P 500 (VOO)

- Ticker to review: IBM
- Cumulative return of review stock: 153.49%
- Cumulative return of comparison stock (S&P 500, VOO): 128.51%
- Divergence: 24.98%
- Relative divergence: 80.30%

**Alpha, Beta Analysis**

| Year       | CAGR   | MDD   | Alpha | Beta | Cap(B) |
|------------|--------|-------|-------|------|---------|
| 2016-2018  | -19.0% | 24.8% | -27.0% | 0.9  | 101.6B  |
| 2017-2019  | -20.0% | 24.8% | -45.0% | 1.0  | 119.8B  |
| 2018-2020  | -12.0% | 37.5% | -35.0% | 1.0  | 112.5B  |
| 2019-2021  | 19.0%  | 37.5% | -45.0% | 0.9  | 124.9B  |
| 2020-2022  | 17.0%  | 37.5% | 13.0%  | 0.8  | 131.7B  |
| 2021-2023  | 53.0%  | 15.2% | 35.0%  | 0.5  | 152.9B  |
| 2022-2024  | 81.0%  | 15.7% | 52.0%  | 0.6  | 205.5B  |
| 2023-2025  | 137.0% | 19.1% | 61.0%  | 0.7  | 276.9B  |

**Recent Stock Price Fluctuations**

- Close: $293.86
- Last-market: -0.83% below the previous close
- 5-day SMA: $294.97
- 20-day SMA: $299.54
- 60-day SMA: $303.05

**RSI, PPO Index indicators, Delta_Previous_Relative_Divergence, Expected_Return**

- Market Risk Indicator (MRI): 0.70
- RSI: 45.04
- PPO: -0.30
- Hybrid Signal: Buy
- Risk Level: Medium (MRI 0.70)
- Recent (20 days) relative divergence change: worsening
- 7-day Rank change: rank down
- 7-day Dynamic Expected Return change: improving
- Expected Return (%): -5.30%

**Recent News & Significant Events**

Based on the provided news headlines, it appears that there are several factors to consider when evaluating IBM's stock performance, including potential Q4 earnings growth, software and infrastructure growth, and free cash flow. Institutional investors are accumulating shares ahead of earnings.

**Analyst Opinions**
- Analyst Consensus:
  - Key: Buy
  - Mean (1=StrongBuy~5=Sell): 2.38 (~Buy)
  - Opinions: 19
  - Target Price (avg/high/low): 305.16 / 375.00 / 210.00

**Recent Earnings Analysis**

| Date | EPS | Revenue |
|-----|----|---------|
| 2025-10-23 | 1.87 | 16.33 B |
| 2025-07-24 | 2.36 | 16.98 B |
| 2025-04-24 | 1.14 | 14.54 B |
| 2024-10-30 | -0.36 | 14.97 B |

The quarterly earnings data suggests that IBM has experienced fluctuating earnings performance, with significant variations in net income. This volatility could have an impact on the company's stock price.

**Financial Information**

**Revenue and Profitability**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | 16.33B | 57.31% |
| 2025-06-30 | 16.98B | 58.77% |
| 2025-03-31 | 14.54B | 55.23% |
| 2024-12-31 | 17.55B | 59.47% |
| 2024-09-30 | 14.97B | 56.26% |

**Capital and Profitability**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | 27.91B | 6.25% |
| 2025-06-30 | 27.51B | 7.98% |
| 2025-03-31 | 26.88B | 3.92% |
| 2024-12-31 | 27.31B | 10.67% |
| 2024-09-30 | 24.45B | -1.35% |

The quarterly data for revenue and profit margin suggests that IBM has experienced fluctuations in revenue and profit margin. The company's ability to maintain and grow profit margins over the long-term will be crucial for its financial performance.

**Comprehensive Analysis (Summary of previous items)**

Based on the analysis of IBM's return rate, alpha and beta analysis, recent stock price fluctuations, RSI and PPO index indicators, analyst opinions, recent earnings analysis, and financial information, there are several factors to consider when evaluating IBM's stock performance. These factors include:

* Significant divergence in cumulative return compared to S&P 500 (VOO)
* Fluctuating earnings performance with significant variations in net income
* Volatility in the company's stock price
* Positive analyst opinions, with a mean rating of Buy and a target price of $305.16
* Moderate market risk indicator (MRI) of 0.70
* Negative expected return percentage of -5.30%

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.